Scapho 150mg (Secukinumab)

Contact us for more information
Wishlist Compare
Brand nameScaphoInternational trade nameCosentyxActive substanceSecukinumabStrength150mgCategoryAnti Cancer

Description of Scapho 150mg (Secukinumab 150mg)

Secukinumab belongs to monoclonal antibody which is a protein which recognises and connect to an inflammatory protein called Interleukin 17A (IL-17A). In patients with psoriatic arthritis and ankylosing spondylitis, the body’s immune system produces an increased amount of IL-17A which causes the symptoms such as swollen and painful joints
Scapho 150mg (Secukinumab 150mg) is a prescription medicines which is used under proper guidance of medical oncologist

Medical use /Indication of Scapho 150mg (Secukinumab 150mg)

Scapho 150mg (Secukinumab 150mg) indicated for the treatment of following condition
Plaque Psoriasis
Psoriatic arthritis
Ankylosing spondylitis.

Mechanism of Action Scapho 150mg (Secukinumab 150mg)

Secukinumab mechanism as Interleukin-17A (IL-17A) is a cornerstone cytokine (messenger protein) contains in the development of psoriasis and is found in peak concentrations in psoriasis plaques.
Secukinumab consist of human IgG1 monoclonal antibody which selectively binds to IL-17A, rapidly prohibiting its pro-inflammatory effects.

Absorption of Scapho 150mg (Secukinumab 150mg)

Maximum plasma concentration for single dose is 6 days and weekly dosing for first month is 31-34 days

Distribution of Scapho 150mg (Secukinumab 150mg)

Volume of distribution is 7.1 – 8.6 (IV administration)

Metabolism of Scapho 150mg (Secukinumab 150mg)

The drug Scapho 150mg (Secukinumab 150mg) is Metabolized via intracellular catabolism.

Excretion of Scapho 150mg (Secukinumab 150mg)

Scapho 150mg (Secukinumab 150mg) has half-life is 22-31 days.

Side effects of Scapho 150mg (Secukinumab 150mg)

  • Infections
  • Nasopharyngitis
  • Diarrhea
  • URT infection
  • Rhinitis
  • Oral herpes
  • Pharyngitis
  • Urticaria
  • Rhinorrhoea

Precautions of Scapho 150mg (Secukinumab 150mg)

Scapho 150mg (Secukinumab 150mg) may have high risk of infections; use with caution in patients with chronic infection or a history of recurrent infection

Before to initiation of Scapho 150mg (Secukinumab 150mg),start with anti-TB therapy in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed

May infuriate Crohn disease

Anaphylaxis and cases of urticaria resulted; if this appears, discontinue Scapho 150mg (Secukinumab 150mg) immediately and start anaphylaxis treatment

Drug interaction of Scapho 150mg (Secukinumab 150mg)

Live vaccinations combination with Scapho 150mg (Secukinumab 150mg) should be avoided
CYP450 substrates concomitant use with Scapho 150mg (Secukinumab 150mg) injection may altered by increased levels of certain cytokines.

Contraindication of Scapho 150mg (Secukinumab 150mg)

Patients having Serious hypersensitivity reactions to the active substance or to any of the excipients

Pregnancy of Scapho 150mg (Secukinumab 150mg)

Pregnancy category is B The drug Scapho 150mg (Secukinumab 150mg)  use with caution during pregnancy

Lactation of Scapho 150mg (Secukinumab 150mg)

Excretion into human milk is unknown

Dosage of Scapho 150mg (Secukinumab 150mg)

Plaque Psoriasis:

Starting dose: given 300 mg SC at weeks 0, 1, 2, 3, and 4

initially at week 8, administer 300 mg SC once monthly

For some patientsmay be acceptable containing dose of 150 mg

Psoriatic Arthritis : 

Indicated for adults with active psoriatic arthritis

Recommended dosage

Psoriatic arthritis for other patients, administer with or without a loading dosage by SC injection

Scapho 150mg (Secukinumab 150mg) with loading dose administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter

Scapho 150mg (Secukinumab 150mg) without loading dose administrated 150 mg SC q4wk.

Consider a dosage of 300 mg, if a patient continues to have active psoriatic arthritis

May be administered with or without methotrexate.

Ankylosing Spondylitis:

Given with or without a loading dosage by SC injection

Scapho 150mg (Secukinumab 150mg) with loading dose is administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter

Scapho 150mg (Secukinumab 150mg) without a loading dose is administrated150 mg SC q4wk

Storage of Scapho 150mg (Secukinumab 150mg)

Store the drug at 2℃ to 8℃.

Missed dose of Scapho 150mg (Secukinumab 150mg)

In case of missed dose, patients must consult with medical practitioner and follow the instructions given by them.
thereby missed dose should be avoid and follow the regular dosing schedule.

Brand name:
International trade name:
Active substance:
Anti Cancer
1 Vial
Product form:

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India